On September 21, 2012, the paper describing the results of our completed Swiss Phase 2 pilot study of MDMA-assisted psychotherapy in 12 subjects with chronic, treatment-resistant PTSD was accepted for publication in the Journal of Psychopharmacology. The paper, co-authored by Clinical Investigator Peter Oehen, M.D., and Ulrich Schneider, M.D., former president of the International Society for Traumatic Stress Studies, the world’s largest organization for PTSD treatment providers and researchers, describes clinically (and almost statistically) significant decreases in PTSD symptoms following MDMA-assisted psychotherapy.
While the small number of subjects in the study contributed to the results approaching but not reaching statistical significance, the mean reductions in PTSD scores were larger than those found in the clinical studies leading to FDA approval for Paxil and Zoloft, the only two currently approved medications for PTSD. Additionally, we were able to generate a successful double blind with therapists and patients both making numerous incorrect guesses about which dose of MDMA had been administered. The paper will be published and available online in February 2013.